Jan 20, 2020 15:21 JST

Source: Eisai

Eisai Rated "A", the Highest Rating in the CDP Climate Change Report 2019


TOKYO, Jan 20, 2020 - (JCN Newswire) - Eisai Co., Ltd. has announced that it has been selected as the highest-rated company "A" in the Climate Change Report 2019 issued by the CDP(1), a non-profit organization, as a company that has performed particularly well in response to climate change.

The CDP is a non-profit organization based in London that requests top-ranking market capitalization companies and municipalities in principal countries to disclose information on climate change, water, and forests. After analyzing and evaluating this information, CDP discloses it to the investors, companies, and government.

Based on the Eisai Network Companies (ENW) Environmental Protection Policy, all employees recognize the importance of environmental protection and conduct business operations seeking co-existence with the global environment. In particular, with regard to climate change, Eisai has positioned it as a key issues facing society, and has set the greenhouse gas emission reduction targets based on the scientific grounds approved by Science Based Targets (SBT) initiative(2) in 2019, and has strengthened its commitment to that goal. In addition, Eisai addresses the reduction of risk and creation of opportunity by capturing the mid- and long-term effects of climate changes to its business utilizing the framework of the Task Force on Climate-related Financial Disclosure (TCFD)(3).

 


Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Under this human health care (hhc) philosophy, Eisai will strengthen its effort on climate change and contribute to ensuring the sustainability of society.

Please refer to the Environmental Report for more detailed information about our environmental activities. https://www.eisai.com/ir/library/annual/index.html

(1) Formerly known as Carbon Disclosure Project.
(2) International joint initiative led by CDP, UN Global Compact (UNGC), World Resources Institute (WRI) and World Wildlife Fund for Nature (WWF).
(3) A private sector-led task force with regard to climate-related financial information disclosure established under the Financial Stability Board (FSB) as per the request of G20 finance ministers and central bank governors.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai: Jyseleca (Filgotinib) Approved in Japan for Rheumatoid Arthritis
September 28 2020 08:04 JST
 
Eisai Receives Positive Opinion from EMA's CHMP on Use of Antiepileptic Agent Fycompa in Pediatric Patients
September 23 2020 08:24 JST
 
Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
September 23 2020 08:10 JST
 
Eisai Presents Latest Data of Phase I Clinical Trial on Liposomal Formulation of Anti-Cancer Agent Halaven (Eribulin) at ESMO Virtual Congress 2020
September 18 2020 10:29 JST
 
Eisai Establishes Pharma Sales Subsidiary in Vietnam
September 17 2020 08:59 JST
 
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2020
September 11 2020 09:41 JST
 
Eisai to Take over Manufacturing and Marketing Approval for Equfina 50mg Tablets (Safinamide Mesilate) in Japan from Meiji Seika Pharma
September 07 2020 08:02 JST
 
Eisai to Launch Sahne Medical Spray and Sahne Medical Cream
August 25 2020 11:55 JST
 
Eisai to Present Latest Data of Lemborexant at 34th Annual Sleep Meeting (SLEEP2020)
August 25 2020 09:30 JST
 
Eisai: Application for Additional Indication of Anti Cancer Agent Lenvima for Unresectable Thymic Carcinoma Submitted in Japan
July 31 2020 08:31 JST
 
More Press release >>

Latest Press Release


More Latest Release >>